Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19038538 | WRN INHIBITORS | January 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 19038543 | WRN INHIBITORS | January 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18999331 | ACYLSULFONAMIDE KAT6A INHIBITORS | December 2024 | April 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18955261 | PHENETHYLAMINES AND CATHINONES PRECURSORS | November 2024 | February 2025 | Allow | 3 | 0 | 0 | No | No |
| 18794551 | PI3K INHIBITORS | August 2024 | December 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18752072 | N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | June 2024 | December 2024 | Allow | 5 | 1 | 1 | No | No |
| 18742438 | PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOF | June 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18732301 | INHIBITORS OF TYK2 | June 2024 | March 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18614911 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | March 2024 | July 2024 | Allow | 4 | 0 | 0 | No | No |
| 18590806 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONS | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18411501 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | January 2024 | April 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18399505 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS AS CK2 INHIBITORS | December 2023 | July 2024 | Allow | 6 | 2 | 0 | No | No |
| 18530071 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | December 2023 | October 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18521462 | SYNTHETIC ROUTE TO 4,4'-DIIODOAZOBENZENE VIA HOMO-OXIDATIVE CROSS-COUPLING OF ARYL DIAZONIUM SALT USING CU-CATALYZED SANDMEYER-STYLE REACTION | November 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18503626 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | November 2023 | June 2024 | Allow | 7 | 0 | 1 | No | No |
| 18497602 | Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists | October 2023 | March 2024 | Allow | 5 | 0 | 1 | No | No |
| 18460063 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | September 2023 | May 2025 | Allow | 21 | 0 | 1 | No | No |
| 18239316 | N'-[(2-CHLOROBENZOYL)OXY]-1,3-BENZOTHIAZOLE-2-CARBOXIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | March 2024 | Allow | 7 | 2 | 0 | No | No |
| 18227186 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | July 2023 | May 2025 | Abandon | 22 | 2 | 0 | Yes | No |
| 18351587 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | July 2023 | March 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18341620 | CRYSTALLINE SALTS OF LINSITINIB | June 2023 | February 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18336279 | METHODS FOR TREATING SOFT TISSUE SARCOMA | June 2023 | May 2025 | Allow | 23 | 1 | 0 | No | No |
| 18035195 | STABLE SALT AND CRYSTAL FORMS OF 2-[3-({1-[2-(DIMETHYLAMINO)ETHYL]-2-(2,2-DIMETHYLPROPYL)-1H-1,3-BENZODIAZOL-5-YL}SULFONYL)AZETIDIN-1-YL]ETHAN-1-OL | May 2023 | December 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 18134695 | 4-ARYLAMINO-2-(6-INDOLYLAMINO)PYRIMIDINE COMPOUNDS AS ANTIBACTERIAL AGENTS | April 2023 | August 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18297368 | DIHYDROFOLATE SYNTHASE (DHFS) INHIBITING AGENTS AND METHODS OF MAKING AND USING SAME | April 2023 | May 2025 | Allow | 25 | 2 | 1 | No | No |
| 18125302 | PYRROLO[3,2-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | August 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18112854 | METHODS OF INHIBITING CYCLOOXYGENASE | February 2023 | July 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18157061 | N-(PYRIMIDO[2,3-b]INDOL-7-YL)ACETAMIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | January 2023 | July 2023 | Allow | 6 | 0 | 1 | No | No |
| 18092606 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER | January 2023 | April 2025 | Abandon | 27 | 2 | 1 | No | No |
| 18145902 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | December 2022 | September 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 18078271 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | December 2022 | September 2024 | Allow | 21 | 1 | 1 | No | No |
| 18072490 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | November 2022 | May 2023 | Allow | 6 | 1 | 0 | No | No |
| 17902701 | INTERMITTENT DOSING OF GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF OVARIAN AND OTHER CANCERS | September 2022 | July 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17879627 | COMPOSITIONS FOR TREATMENT OF OCULAR DISEASES | August 2022 | May 2023 | Allow | 10 | 0 | 0 | No | No |
| 17791694 | CRYSTAL FORM OF PYRROLIDINYL UREA DERIVATIVE AND APPLICATION THEREOF | July 2022 | March 2023 | Allow | 8 | 0 | 0 | Yes | No |
| 17858321 | CRYSTALLINE FORMS OF (S, E)-4-(DIMETHYLAMINO)-N-(3-(4-(2-HYDROXY-1-PHENYLETHYLAMINO)-6-PHENYLFURO[2,3-D]PYRIMIDIN-5-YL)PHENYL)BUT-2-ENAMIDE FREE BASE | July 2022 | November 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17780890 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | May 2022 | May 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17696610 | Mi-2beta Inhibitor as an Immunotherapy Agent | March 2022 | April 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17694311 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | March 2022 | July 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17694642 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | March 2022 | September 2023 | Allow | 18 | 0 | 1 | Yes | No |
| 17690851 | GLP-1R MODULATING COMPOUNDS | March 2022 | March 2024 | Allow | 24 | 1 | 1 | No | No |
| 17670397 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | February 2022 | November 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17586962 | METHODS OF TREATING INFLAMMATORY DISEASES | January 2022 | May 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17570809 | COMBINED MAPK AND NAMPT INHIBITION FOR TREATMENT OF NEURON DEGENERATION | January 2022 | March 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17568474 | DEXMEDETOMIDINE TREATMENT REGIMENS | January 2022 | January 2025 | Abandon | 36 | 3 | 0 | No | No |
| 17566695 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | December 2021 | June 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17559280 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | December 2021 | June 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17557860 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | December 2021 | August 2023 | Allow | 20 | 1 | 1 | No | No |
| 17552491 | COMPOSITIONS FOR TARGETING RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) IN A CHRONIC INFLAMMATORY CONDITION | December 2021 | February 2024 | Allow | 26 | 2 | 1 | No | No |
| 17552396 | BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS | December 2021 | September 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17616205 | Imidazopyrazine Derivatives and the Use Thereof as Medicament | December 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17600976 | Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer | November 2021 | March 2025 | Allow | 41 | 1 | 0 | No | No |
| 17594889 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SPINAL CORD INJURY OR SPINAL STENOSIS | November 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17512268 | AQUEOUS FORMULATIONS OF WATER INSOLUBLE COX-2 INHIBITORS | October 2021 | July 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17488139 | [6R]-MTHF IN 5-FU BASED CHEMOTHERAPY OF BRAF- OR KRAS-MUTATED COLORECTAL CANCER | September 2021 | October 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17488079 | [6R]-MTHF IN 5-FU BASED CHEMOTHERAPY OF RIGHT-SIDED COLORECTAL CANCER | September 2021 | October 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17437944 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17464390 | PHARMACEUTICAL COMPOSITIONS OF VIBEGRON FOR REDUCING BODY FAT | September 2021 | June 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17426951 | y-AMINOBUTYRIC ACID MODULATOR CRYSTAL FORM X, PREPARATION METHOD AND APPLICATION THEREOF | July 2021 | July 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17376355 | PREMIXED, READY TO USE PHARMACEUTICAL COMPOSITIONS OF AMIODARONE | July 2021 | October 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17367832 | Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same | July 2021 | January 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17415821 | CRYSTALLINE FORM OF PROPOXAZEPAM, THE METHOD OF ITS MAKING AND USE AS MEDICINAL AGENT | June 2021 | June 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17294819 | BIS-INDOLYLMETHANE DERIVATIVES AND USES THEREOF | May 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17290386 | TREATMENT OF INFLAMMATORY CONDITIONS | April 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17290357 | NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17235518 | ZINC AND COPPER FOR THE PROPHYLAXIS AND TREATMENT OF COVID-19 | April 2021 | August 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17283410 | CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | April 2021 | April 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17283301 | CRYSTALLINE POLYMORPHS OF BRUTON'S TYROSINE KINASE INHIBITORS | April 2021 | June 2023 | Allow | 27 | 0 | 0 | No | No |
| 17282358 | Crystalline Forms of Niraparib Freebase | April 2021 | May 2024 | Allow | 37 | 2 | 0 | No | No |
| 17282378 | ITRACONAZOLE ANALOGS AND USE THEREOF | April 2021 | March 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17281528 | SOLID FORMS OF N-(4-FLUORO-3-(6-(3-METHYLPYRIDIN-2-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-YL)PHENYL)-2,4-DIMETHYLOXAZOLE-5-CARBOXAMIDE | March 2021 | September 2023 | Allow | 30 | 0 | 1 | Yes | No |
| 17278163 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | March 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17275175 | COMBINATION THERAPIES | March 2021 | June 2025 | Abandon | 51 | 3 | 1 | No | No |
| 17272276 | KRAS G12C INHIBITORS | February 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17269814 | PYRROLIDINE GLYCOSIDASE INHIBITORS | February 2021 | February 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17267362 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | February 2021 | May 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17267003 | L-THEANINE AND TETRAHYDROCANNABINOL FORMULATION | February 2021 | January 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17170172 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | February 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17264670 | CDK8/19 INHIBITORS | January 2021 | July 2023 | Allow | 30 | 1 | 1 | No | No |
| 17262032 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | January 2021 | December 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17261430 | ACTIVATOR FOR SIMULTANEOUSLY ACTIVATING OXIDATIVE PHOSPHORYLATION AND INHIBITING GLYCOLYSIS AND USE THEREOF | January 2021 | November 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17260856 | SIDEROPHORE CONJUGATED PYRAZOLIDINONES, AND ANALOGUES THEREOF | January 2021 | April 2023 | Allow | 27 | 0 | 0 | No | No |
| 17260711 | Modulators of RAS GTPase | January 2021 | November 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 17050800 | PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE | January 2021 | August 2023 | Allow | 33 | 1 | 0 | No | No |
| 17257804 | PqsR INVERSE AGONISTS | January 2021 | August 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17255642 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | December 2020 | April 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17255264 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | December 2020 | February 2023 | Allow | 26 | 1 | 0 | No | No |
| 17041840 | COMPOSITIONS FOR PREVENTING OR TREATING COGNITIVE IMPAIRMENT-RELATED DISEASE COMPRISING MUMEFURAL | December 2020 | June 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17126501 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | December 2020 | August 2023 | Allow | 32 | 2 | 1 | No | No |
| 17253346 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | December 2020 | October 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17111432 | TETRAHYDROCANNABINOLIC- AND CANNABIDIOLIC ACID DERIVATIVES AND USES THEREOF | December 2020 | November 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17105060 | ISOINDOLINONE DERIVATIVES AS SELECTIVE ALLOSTERIC INHIBITORS OF EGFR MUTANT CANCERS | November 2020 | March 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17101942 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | November 2020 | July 2024 | Allow | 44 | 1 | 0 | No | No |
| 17056450 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | November 2020 | February 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17094572 | NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES | November 2020 | April 2024 | Allow | 41 | 1 | 0 | No | No |
| 17053984 | METHODS FOR TREATING OR LIMITING DEVELOPMENT OF CARDIOVASCULAR DISEASE-RELATED NEUROLOGICAL DISORDERS | November 2020 | July 2023 | Allow | 32 | 2 | 1 | No | No |
| 17053380 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | November 2020 | October 2024 | Allow | 48 | 2 | 0 | No | No |
| 17090548 | Salt Forms Of 4-Cyano-N-(4,4-Dimethylcyclohex-1-EN-1-YL)-6-(2,2,6,6-Tetramethyltetrahydro-2H-Pyran-4-YL)Pyridin-3-YL)-1H-Imidazole-2-Carboximide | November 2020 | January 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17048373 | ELECTROLUMINSCENT MATERIAL CONTAINING CARBONYL GROUP, AND APPLICATION THEREOF TO OLED | October 2020 | April 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17071953 | COMBINATION THERAPY WITH A BET INHIBITOR AND A PROTEASOME INHIBITOR | October 2020 | April 2024 | Abandon | 42 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAO, PADMAJA S.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RAO, PADMAJA S works in Art Unit 1627 and has examined 109 patent applications in our dataset. With an allowance rate of 67.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner RAO, PADMAJA S's allowance rate of 67.9% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAO, PADMAJA S receive 1.33 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by RAO, PADMAJA S is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +42.8% benefit to allowance rate for applications examined by RAO, PADMAJA S. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 23.1% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 20.0% are granted (fully or in part). This grant rate is in the 11% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.